Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

Age-dependent neuroplasticity mechanisms in Alzheimer Tg2576 mice following modulation of brain amyloid-β levels.

Lilja AM, Röjdner J, Mustafiz T, Thomé CM, Storelli E, Gonzalez D, Unger-Lithner C, Greig NH, Nordberg A, Marutle A.

PLoS One. 2013;8(3):e58752. doi: 10.1371/journal.pone.0058752. Epub 2013 Mar 15.

2.

Icariin decreases both APP and Aβ levels and increases neurogenesis in the brain of Tg2576 mice.

Li F, Dong HX, Gong QH, Wu Q, Jin F, Shi JS.

Neuroscience. 2015 Sep 24;304:29-35. doi: 10.1016/j.neuroscience.2015.06.010. Epub 2015 Jun 12.

PMID:
26079110
3.

Effects of donepezil on amyloid-beta and synapse density in the Tg2576 mouse model of Alzheimer's disease.

Dong H, Yuede CM, Coughlan CA, Murphy KM, Csernansky JG.

Brain Res. 2009 Dec 15;1303:169-78. doi: 10.1016/j.brainres.2009.09.097. Epub 2009 Sep 30.

4.

Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease.

Snellman A, López-Picón FR, Rokka J, Salmona M, Forloni G, Scheinin M, Solin O, Rinne JO, Haaparanta-Solin M.

J Nucl Med. 2013 Aug;54(8):1434-41. doi: 10.2967/jnumed.112.110163. Epub 2013 Jul 5.

5.

Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease.

Manczak M, Mao P, Nakamura K, Bebbington C, Park B, Reddy PH.

Hum Mol Genet. 2009 Oct 15;18(20):3876-93. doi: 10.1093/hmg/ddp331. Epub 2009 Jul 19.

6.

Neural Stem Cell Transplant-Induced Effect on Neurogenesis and Cognition in Alzheimer Tg2576 Mice Is Inhibited by Concomitant Treatment with Amyloid-Lowering or Cholinergic α7 Nicotinic Receptor Drugs.

Lilja AM, Malmsten L, Röjdner J, Voytenko L, Verkhratsky A, Ögren SO, Nordberg A, Marutle A.

Neural Plast. 2015;2015:370432. doi: 10.1155/2015/370432. Epub 2015 Jul 15.

7.

Neurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease.

Lilja AM, Luo Y, Yu QS, Röjdner J, Li Y, Marini AM, Marutle A, Nordberg A, Greig NH.

PLoS One. 2013;8(1):e54887. doi: 10.1371/journal.pone.0054887. Epub 2013 Jan 30.

8.

Effects of corticotrophin-releasing factor receptor 1 antagonists on amyloid-β and behavior in Tg2576 mice.

Dong H, Wang S, Zeng Z, Li F, Montalvo-Ortiz J, Tucker C, Akhtar S, Shi J, Meltzer HY, Rice KC, Csernansky JG.

Psychopharmacology (Berl). 2014 Dec;231(24):4711-22. doi: 10.1007/s00213-014-3629-8. Epub 2014 May 27.

9.

Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease.

Paris D, Ganey NJ, Laporte V, Patel NS, Beaulieu-Abdelahad D, Bachmeier C, March A, Ait-Ghezala G, Mullan MJ.

J Neuroinflammation. 2010 Mar 8;7:17. doi: 10.1186/1742-2094-7-17.

10.

Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG.

J Neurosci. 2001 Jan 15;21(2):372-81.

11.

Effect of huprine X on β-amyloid, synaptophysin and α7 neuronal nicotinic acetylcholine receptors in the brain of 3xTg-AD and APPswe transgenic mice.

Hedberg MM, Clos MV, Ratia M, Gonzalez D, Lithner CU, Camps P, Muñoz-Torrero D, Badia A, Giménez-Llort L, Nordberg A.

Neurodegener Dis. 2010;7(6):379-88. doi: 10.1159/000287954. Epub 2010 Aug 4.

PMID:
20689242
12.

Advanced glycation endproducts and pro-inflammatory cytokines in transgenic Tg2576 mice with amyloid plaque pathology.

Münch G, Apelt J, Rosemarie-Kientsch-Engel, Stahl P, Lüth HJ, Schliebs R.

J Neurochem. 2003 Jul;86(2):283-9.

13.

Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid.

Nichol KE, Poon WW, Parachikova AI, Cribbs DH, Glabe CG, Cotman CW.

J Neuroinflammation. 2008 Apr 9;5:13. doi: 10.1186/1742-2094-5-13.

14.

Hippocampal administration of chondroitinase ABC increases plaque-adjacent synaptic marker and diminishes amyloid burden in aged APPswe/PS1dE9 mice.

Howell MD, Bailey LA, Cozart MA, Gannon BM, Gottschall PE.

Acta Neuropathol Commun. 2015 Sep 4;3:54. doi: 10.1186/s40478-015-0233-z.

15.

Impacts of aging and amyloid-β deposition on plasminogen activators and plasminogen activator inhibitor-1 in the Tg2576 mouse model of Alzheimer's disease.

Bi Oh S, Suh N, Kim I, Lee JY.

Brain Res. 2015 Feb 9;1597:159-67. doi: 10.1016/j.brainres.2014.11.042. Epub 2014 Nov 29.

PMID:
25454795
16.

Treadmill exercise enhances synaptic plasticity, but does not alter β-amyloid deposition in hippocampi of aged APP/PS1 transgenic mice.

Zhao G, Liu HL, Zhang H, Tong XJ.

Neuroscience. 2015 Jul 9;298:357-66. doi: 10.1016/j.neuroscience.2015.04.038. Epub 2015 Apr 23.

PMID:
25917310
17.
18.

Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice.

Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA.

J Neurosci. 2008 Jun 18;28(25):6333-41. doi: 10.1523/JNEUROSCI.0829-08.2008.

19.

Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.

Zhang W, Hao J, Liu R, Zhang Z, Lei G, Su C, Miao J, Li Z.

Behav Brain Res. 2011 Sep 23;222(2):342-50. doi: 10.1016/j.bbr.2011.03.072. Epub 2011 Apr 14.

PMID:
21513747
20.

The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.

Collins JM, King AE, Woodhouse A, Kirkcaldie MT, Vickers JC.

Exp Neurol. 2015 May;267:219-29. doi: 10.1016/j.expneurol.2015.02.034. Epub 2015 Mar 4.

PMID:
25747037

Supplemental Content

Support Center